Kyle Bartholomew, DVM, DACVAA, discusses how a multimodal plan for treating pain with analgesics can lead to improved outcomes.

Using multimodal analgesic plans to manage pain

 interview at the North American Veterinary Community (NAVC) SkillShop in Orlando, Florida, Kyle Bartholomew, DVM, DACVAA, clinical assistant professor of veterinary anesthesia at the University of Wisconsin School of Veterinary Medicine, discusses how multimodal analgesic plans can benefit patients experiencing pain. Bartholomew recently served as an instructor for the Small Animal Anesthesia for the Practice Team course at the continuing education event. He presented lectures and provided lab instruction with colleagues over 4 days, including a session on balanced anesthesia and analgesia.

The following is a transcript of the video:

Multimodal analgesic plans can benefit patients by combining multiple analgesics for 1 painful condition. The reason we use multimodal analgesia is because pain is incredibly complicated, so each patient can benefit from attacking it via different pathways with different analgesics. Also, the analgesics we use often have some [adverse] effects. People think of ileus or nausea, [gastrointestinal] upset with opioids—those will also increase the higher the dose goes. So, we use multiple analgesics combined...to help reduce the negative [adverse] effects that patients can experience with high doses of each individual analgesic.

Training new leaders with CPR instructor certification course

Kenichiro Yagi, MS, RVT, VTS (ECC, SAIM), program director for the RECOVER Initiative; and Dan Fletcher, DVM, PhD, DACVECC, cochair of the RECOVER Initiative, discuss the RECOVER CPR course. Additionally, new instructors Jennifer Dow, RVT, VTS (ECC); and Anita Parker, RVN, AVN, VTS (Anesthesia & Analgesia), CVPP, talk about what they’ve gained from hands-on experience.

: La'Toya Latney, DVM, DECZM (ZHM), DABVP (Reptile & Amphibian), CertAqV, senior veterinarian at The Schwarzman Animal Medical Center in New York, New York, provides insights for general practitioners caring for chelonians and how practices can use tools they already have in the clinic to examine turtles, terrapins, and tortoises.

Using total intravenous anesthesia in certain cases

: Marlis Rezende, DVM, PhD, MSc, DACVAA, an associate professor of anesthesia and pain management at Colorado State University College of Veterinary Medicine and Biological Sciences in Fort Collins, discusses total intravenous anesthesia and the common conditions she sees in practice that best utilize this method of pain management.

Articles

Kyle Bartholomew, DVM, DACVAA, discusses how combining treatment options can lead to improved outcomes.

Happy Monday dvm360 readers! Did you know that the dvm360 team attended the 2025 American College of Veterinary Internal Medicine (ACVIM) Forum in Louisville, Kentucky last week? The team took the conference by storm with lecture coverage, interviews with faculty, and news coming from the ACVIM Forum! You can check out dvm360’s conference coverage on our dedicated 

 and if you are looking for coverage on WVC, VMX, Fetch Conferences, and other veterinary conferences, check out our 

After checking out our conference coverage, be on the lookout for these articles, interviews, and podcast episode this week:

Kelly Chapell, DVM, DACVIM (Small Animal), takes readers into a deep dive to get a better understanding and management of coccidiomycosis, also known as Valley Fever, in veterinary patients.

Medetomidine, a racemic mixture of dexmedetomidine and levomedetomidine, is a rising concern for health officials in the United States because it has become a dangerous adulterant in the United States illegal drug supply.

On this week’s episode of The Vet Blast Podcast presented by dvm360, Adam Christman, DVM, MBA, welcomes veterinary student and dvm360 student ambassador Sophia Jodka to the podcast to discuss her role in planning the APVMA 2024 symposium, and how other students can get involved in organized veterinary medicine.

Pet Poison Helpline recently shared its latest installment of its 

which details the story of Kaya, a dog from Amana, Iowa, who ingested dalfampridine, which helps improve walking in patients with multiple sclerosis and ataxia, which can impact coordination and balance.

During an interview with Christman, Carolina Monk, DVM, DACVO, from Blue Pearl Malvern, breaks down some topics that general practitioners can come across for ophthalmology cases in the general practice.

Banfield Animal Hospital announced that it has surveyed over 5000 pet owners in the United States to learn more about pet owner superlatives state by state such as South Carolina being ranked number 1 for never missing their pet’s flea and tick treatment as well as having a wellness plan.

Here is a sneak peek at this week’s headlines 

Sneak peek: Medetomidine now identified in the US illegal drug supply, and other news 

Resident researchers were recognized and applauded at the 2025 American College of Veterinary Internal Medicine (ACVIM) Forum in Louisville, Kentucky, during an awards luncheon on June 20, 2025. The special event was sponsored by Purina Institute, with many of the winners in attendance. The winning abstracts were among the research presented to ACVIM Forum attendees throughout the conference.

Resident Research Abstract Award winners gather on stage to be recognized at the 2025 ACVIM Forum in Louisville, Kentucky. 

The 2025 ACVIM Resident Research Abstract Award winners and their recognized works are as follows:

Cassidy M. Coats, DVM; Colorado State University in Fort Collins—“Coronary Ostial Eccentricity, Aortic Rotation, and Cusp Symmetry in Dogs Evaluated by Cardiac Computed Tomography”

Kiersten K. Forsyth, DVM; Purdue University in West Lafayette, Indiana—“Effects of Zenalpha (Medetomidine/Vatinoxan) on Blood Pressure, Echocardiographic Measurements, and Cardiac Rhythm in Healthy Dogs”

Eline Nijveldt, DVM; The Ohio State University in Hilliard—"Echocardiographic Evaluation of Aortic Root Size in Cats With Hypertrophic Cardiomyopathy”

Florence Dupuis-Dowd, DVM, MSc; University of California, Davis—"Effect of Ertugliflozin on Glucose and Insulin Dynamics in Healthy Horses Receiving Dexamethasone”

Evelyn Hodgson, DVM; University of Queensland in Australia—“Prolongs Wireless Measurement of Intragastric pH in Foals”

Large-Animal Medicine Internal Medicine (Food Animal)

Caitlyn Mullins, DVM, MS; Kansas State University in Manhattan—"Dual-Center Retrospective Review of 204 Transfusions in Camelids”

Jessica Linder, DVM, BS; Purdue University—“Spinal-Only Meningomyelitis of Unknown Etiology: Clinical Presentation, Diagnosis, Treatment, and Outcome in 23 Dogs”

Alejandra Mondino, DVM, PhD; North Carolina State University in Raleigh—“Dissolution Characteristics of Split and Crushed Levetiracetam Extended-Release Tablets in Comparison With Immediate-Release Formulation”

Dana Ford, DVM; The Ohio State University in Columbus—"Increasing Dietary Fiber Intake Improves Fecal and Clinical Activity Scores in Dogs With Chronic Enteropathy”

Kayla Neiderfer, DVM; Oregon State University in Corvallis—“Comparison of Pooled vs Single Samples Measuring Urine Protein: Creatine Ratio in Dogs Receiving Toceranib Phosphate”

Carly Iulo, DVM; Auburn University College of Veterinary Medicine in Alabama—“Plasma Plasminogen Activator Inhibitor (PAI-1) Activity in Dogs With Immune-Mediated Hemolytic Anemia”

Kayla Prentice, DVM; Tufts University in Grafton, Massachusetts—"Do Serum Pro-Inflammatory and Pro-Coagulant Biomarkers in Dogs With Gallbladder Mucoceles Predict Disease Progression?”

Max Randolph, DVM; University of California, Davis—“Outbreak of Leptospirosis in Dogs From Los Angeles County, California, USA 2021”

Colin Smith, DVM; University of Tennessee in Knoxville—“Effect of Low Dose Azithromycin on the Fecal Microbiome and Fecal Bile Acids in Dogs”

Sierrah Travis, DVM, BS; Virginia-Maryland College of Veterinary Medicine in Blacksburg, Virginia—“Plasma ADAMTS13 Activity in Dogs With Severe Thrombocytopenia and Presumed Immune Thrombocytopenia”

2025 ACVIM Resident Research Abstract Awards. Presented at: American College of Veterinary Internal Medicine Forum; June 18-21, 2025; Louisville, KY.

Fifteen honorees were recognized for their investigative work in various specialities. 

Resident Research Abstract Award winners are celebrated at 2025 ACVIM Forum

Jeffrey N. Bryan, DVM, PhD, MS, DACVIM, discusses the need for a new treatment option for dogs with osteosarcoma in a dvm360 interview.

Considering treatment options with canine osteosarcoma

Treatment of canine osteosarcoma is advancing with recently released data showing enhanced outcomes for patients with a combination of chemotherapy and ELIAS Cancer Immunotherapy (ECI). In a 

2025 American College of Veterinary Internal Medicine (ACVIM) Forum 

in Louisville, Kentucky, Jeffrey N Bryan, DVM, PhD, MS, DACVIM, professor of oncology and associate director of the Ellis Fischel Cancer Center at the University of Missouri in Columbia, Missouri and principal investigator for the pilot trial for ECI, discussed current treatment options for bone cancer in dogs and how science and technology are providing new avenues of care, such as ECI.

New data for novel bone cancer therapy demonstrates improved outcomes

: Osteosarcoma is a primary cancer of bone, and unlike most cancers that are not terribly painful, it is extremely painful. So the patients that come to us, we talk about having problems of life and limb and the limb part really is pain and severe life limiting discomfort. So removal of that tumor, either by surgery on the tumor itself, or amputation or using radiation to control it, becomes primary in managing the limb part of it. However, the majority of these patients, when they present, will already have microscopic spread of their tumor elsewhere in their body, particularly to their lungs, and that is what really limits their survival, their life.

If we only amputate dogs, half of them will be gone in the first few months after amputation, which is a terrible outcome, and the rest of them will almost certainly be gone long before a year happens if we add chemotherapy to amputation, they live two to three times longer than if they have amputation alone, based on the published literature. And so now, adding a dose of chemotherapy while we wait to start the immunotherapy, and having survivals that are well out over a year in this group of dogs, as well as more than half of them being alive at the 1 year mark, appears to be a very substantial advance forward. The fact that this is a well-tolerated treatment that invokes the dog's own immune system to try to control the disease long term is a substantial advancement over what we have had in the past to treat these patients.

Videos

Jeffrey N. Bryan, DVM, PhD, MS, DACVIM, discusses current methods and the need for advancement in how bone cancer is managed in dogs

Considering treatment options for canine osteosarcoma

New, promising clinical study results for an autologous prescription product used in combination with chemotherapy to treat canine osteosarcoma were presented by ELIAS Animal Health, a companion animal cancer therapeutics company, at the 2025 American College of Veterinary Internal Medicine (ACVIM) Forum in Louisville, Kentucky. The interim analysis of ELIAS Cancer Immunotherapy (ECI) demonstrated improved outcomes by combining the initial cytotoxic effects of chemotherapy with the targeted immune-mediated response stimulated by ECI, which has the potential to enhance overall response and survival rates in dogs with cancer, according to the company.

“The hypothesis of putting a dose of chemotherapy in front of the immunotherapy does appear to produce even better outcomes than what we would have expected,” Tammie Wahaus, CEO of ELIAS Animal Health, said in a 

interview at the ACVIM Forum. The oral abstract, “Adoptive Cell Therapy With Chemotherapy Improves Canine Osteosarcoma Outcomes Compared to Standard of Care Chemotherapy,” was presented by Jeffrey N. Bryan, DVM, PhD, MS,  DACVIM, professor of oncology and associate director of the Ellis Fischel Cancer Center at the University of Missouri in Columbia, Missouri, and principal investigator for the pilot trial for ECI, who shared with attendees that the combined therapeutic approach showed improved outcomes and was well tolerated.

In the study, 14 dogs received 1 dose of carboplatin, which was followed by ECI 21 days later. This treatment group showed the best response, with a 1-year survival rate of 71% compared with 21% in 14 matched control dogs newly diagnosed with osteosarcoma that received 4 doses of carboplatin only, which is the current standard of care, according to ELIAS Animal Health.

“We think that’s meaningful. We think it’s exciting, and we look forward to following these dogs to the point where we can report out an 18-month survival rate on an even bigger population of dogs,” Wahaus said.

“We’re excited to share these results at the 2025 ACVIM Forum and look forward to the final study results, which are expected in late 2026. We believe this interim analysis provides important clinical insights into how veterinarians treating cancer are integrating ECI into their treatment protocols,” she added in a news release.

Bryan said that, as a practicing oncologist, there are 2 exciting takeaways with ECI and the latest advancement. “One, it shows that we can combine the type of therapy that our practitioners are used to, chemotherapy, with this immunotherapy. Two, it likely gives an expectation that more than half the dogs could be alive a year after you start treatment, and there really are not many options in osteosarcoma that have that kind of likelihood. This, if it holds, continues to be a significant movement of the needle for dogs that suffer from this terrible bone cancer,” he said in a 

ECI was approved by the US Department of Agriculture (USDA) Center for Veterinary Biologics in March 2025.

 This is the only USDA-approved treatment for canine osteosarcoma, and it works as a personalized cancer vaccine that is combined with activated T cells that target cancer cells. ECI is currently available at authorized treatment centers in the US.

New study data on chemo-immunotherapy approach using the ELIAS Cancer Immunotherapy (ECI) to treat bone cancer in dogs demonstrates improved outcomes. News release. ELIAS Animal Health. June 19, 2025. Accessed June 20, 2025. 

https://eliasanimalhealth.com/news/eci-combined-with-chemo-shows-improved-outcomes/

McCafferty C. USDA approves new canine cancer therapy. 

. March 19, 2025. Accessed June 20, 2025. 

https://www.dvm360.com/view/usda-approves-new-canine-cancer-therapy

ELIAS Cancer Immunotherapy was combined with chemotherapy in a study with results presented at the 2025 ACVIM Forum.

A study presented at the 2025 American College of Veterinary Internal Medicine (ACVIM) Forum in Louisville, Kentucky, on 375 cats with a first lifetime diagnosis of diabetes in the United Kingdom found that age 15 years or greater was a risk factor for failure to receive antihyperglycemic therapy and early mortality (less than or equal to 30 days).

 The research was presented by Oliver Waite, BVSc, MVetMed, DACVIM (SAIM), MRCVS, senior lecturer in small animal medicine at The Animal Hospital of Murdoch University in Western Australia, Australia.

Approximately 1 in 100 to 1 in 500 cats will be diagnosed with diabetes in their lifetime.

During his presentation, Waite shared that up to 10% of cats on high-dose prednisone may develop diabetes, with more than 85% of these patients developing the disease within 3 months of therapy.

 He also noted that neutering males acts as a risk factor for developing diabetes.

Twenty percent of feline patients diagnosed with diabetes do not receive antihyperglycemic therapy.

 “There's limited information describing these events, so there doesn't appear to be a lot of information pertaining patient signalment, presenting clinical signs, [or] laboratory tests performed at or around the time of diagnosis,” said Waite, speaking of the statistics of feline patients with diabetes who do not receive antihyperglycemic therapy.

Additionally, up to 20% of cats will die within 30 days following their first lifetime diagnosis of diabetes, although for this, there is also limited information explaining why, according to Waite. “It's even more...alarming when we look at how many cats are euthanized,” he said during his presentation. “Euthanasia is the overwhelming cause of mortality, and I suppose it would be the case that these cats are euthanized either because of their diabetes or because diabetes is part of their concurrent problem. But again, it's a little bit hard to kind of tease apart these cats—were they actually treated with antihyperglycemic therapy [and] died and or were [they] euthanized within [the treatment] period?”

The study, an anonymized retrospective cohort study, used electronic health records from VetCompass, a UK-based program that extracts and analyzes clinical data from veterinary practices in the country. Using this program, electronic health records from cats seeing UK veterinary primary care practices between January 1, 2019, and December 31, 2019, were identified and reviewed. Multivariable logistic regression and Cox proportional hazard models were then performed, including risk factors (

<0.2) associated with cats who were not receiving antihyperglycemic therapy and a ≤30 mortality (

According to Waite, the most common presenting clinical signs reported in the primary care practice electronic health records were polydipsia, weight loss, and polyuria. Signs associated with diabetic neuropathy or diabetic ketoacidosis were infrequently reported in the health records. Still, presenting clinical signs, comorbidities, and laboratory tests were not found to be associated with less than or equal to 30-day mortality.

More than 80% (n=310) of the cats in the study received antihyperglycemic therapy. Yet, approximately 10% of treated cats still suffered mortality within 30 days of diagnosis. Sixty-five did not receive antihyperglycemic therapy.

Being aged 15 years or older was identified as the only factor significantly associated with increased odds of not receiving antihyperglycemic therapy as well as increased mortality within 30 days after starting therapy in both analyses.

“We know that age is not a disease—it's something that we're all told...But here it's really hard to ignore [since] it appears to drastically influence decisions and outcomes to these patients,” said Waite.

Waite explained that this baseline information will be necessary to benchmark future outcomes, especially as new therapies like SGLT-2 inhibitors emerge. “We're going to need this baseline information to fall back on to decide how significant the use of SGLT2 inhibitors is in terms of improving patient quality of life [and] compliance, reducing morbidity and/or mortality,” he said.

Waite O. Risk Factors Against Treating Cats with Diabetes Mellitus and ≤30-day Survival After Starting Anti-Hyperglycaemic Therapy. Presented at: American College of Veterinary Internal Medicine (ACVIM) Forum; June 18-21, 2025. Louisville, KY.

Feline diabetes. Cornell University College of Veterinary Medicine. Accessed June 20, 2025. https://www.vet.cornell.edu/departments-centers-and-institutes/cornell-feline-health-center/health-information/feline-health-topics/feline-diabetes

The study, presented at the 2025 ACVIM Forum, found that cats aged greater than or equal to 15 years old were less likely to receive antihyperglycemic therapy.